





- Combining strong pushability, kink resistance and flexibility
- Support for contralateral maneuvers
- Large inflation lumen for fast deflation times



Proprietary Coating Technology

- Durable paclitaxel carrier for optimized drug delivery
- Uniform coating of balloon treatment area
- Paclitaxel dose=3 μg/mm²

Special low friction double coating

Facilitates lesion crossing





AcoArt Litos Extremely Deep

Technical specifications:	
Catheter design	OTW (over-the-wire)
Shaft diameter	4F
Usable shaft length	90 / 150 cm
Guidewire compatibility	0.014"
Introducer Sheath	4F
Low friction coating	Dual shaft lubrication
Balloon marker	2
Balloon nominal pressure (NP)	6 bar



AcoArt Litos Drug Eluting Balloon Catheter

Ref. N° Usable length 90 cm	Ref. N° Usable length 150 cm	Balloon Ø (mm)	Balloon length (mm)	Recom. introducer (F)	RBP (bar)
LTS20020CG	LTS20020DG	2	20	4	18
LTS20030CG	LTS20030DG	2	30	4	18
LTS20040CG	LTS20040DG	2	40	4	18
LTS20060CG	LTS20060DG	2	60	4	18
LTS20080CG	LTS20080DG	2	80	4	18
LTS20100CG	LTS20100DG	2	100	4	18
LTS20120CG	LTS20120DG	2	120	4	18
LTS20150CG	LTS20150DG	2	150	4	16
LTS20200CG	LTS20200DG	2	200	4	16
LTS20250CG	LTS20250DG	2	250	4	16
LTS20300CG	LTS20300DG	2	300	4	16
LTS25020CG	LTS25020DG	2.5	20	4	18
LTS25030CG	LTS25030DG	2.5	30	4	18
LTS25040CG	LTS25040DG	2.5	40	4	18
LTS25060CG	LTS25060DG	2.5	60	4	18
LTS25080CG	LTS25080DG	2.5	80	4	18
LTS25100CG	LTS25100DG	2.5	100	4	18
LTS25120CG	LTS25120DG	2.5	120	4	18
LTS25150CG	LTS25150DG	2.5	150	4	16
LTS25200CG	LTS25200DG	2,5	200	4	16
LTS25250CG	LTS25250DG	2.5	250	4	16
LTS25300CG	LTS25300DG	2.5	300	4	16
LTS30020CG	LTS30020DG	3	20	4	18
LTS30030CG	LTS30030DG	3	30	4	18
LTS30040CG	LTS30040DG	3	40	4	18
LTS30060CG	LTS30060DG	3	60	4	18
LTS30080CG	LTS30080DG	3	80	4	18
LTS30100CG	LTS30100DG	3	100	4	18

Ret, N° Usable length 90 cm	Ref. N° Usable length 150 cm	Balloon Ø (mm)	Balloon length (mm)	Recom. introducer (F)	RBP (bar)
LTS30120CG	LTS30120DG	3	120	4	18
LTS30150CG	LTS30150DG	3	150	4	16
LTS30200CG	LTS30200DG	3	200	4	16
LTS30250CG	LTS30250DG	3	250	4	16
LTS30300CG	LTS30300DG	3	300	4	16
LTS35020CG	LTS35020DG	3.5	20	4	18
LTS35030CG	LTS35030DG	3.5	30	4	18
LTS35040CG	LTS35040DG	3.5	40	4	18
LTS35060CG	LTS35060DG	3.5	60	4	18
LTS35080CG	LTS35080DG	3.5	80	4	18
LTS35100CG	LTS35100DG	3.5	100	4	18
LTS35120CG	LTS35120DG	3.5	120	4	18
LTS35150CG	LTS35150DG	3.5	150	4	16
LTS35200CG	LTS35200DG	3.5	200	4	16
LTS35250CG	LTS35250DG	3.5	250	4	16
LTS35300CG	LTS35300DG	3.5	300	4	16
LTS40020CG	LTS40020DG	4	20	4	18
LTS40030CG	LTS40030DG	4	30	4	18
LTS40040CG	LTS40040DG	4	40	4	18
LTS40060CG	LTS40060DG	4	60	4	18
LTS40080CG	LTS40080DG	4	80	4	18
LTS40100CG	LTS40100DG	4	100	4	18
LTS40120CG	LTS40120DG	4	120	4	18
LTS40150CG	LTS40150DG	4	150	4	16
LTS40200CG	LTS40200DG	4	200	4	16
LTS40250CG	LTS40250DG	4	250	4	16
LTS40300CG	LTS40300DG	4	300	4	16

Ref N° Ref N° Ralloon Ralloon Recom --

Code instructions


LTS35020CG

Usable shaft length: CG-90cm DG-150cm

Version:2.0 Publication date:2020-0605

Acotec Scientific Co., Ltd. fax: +86 10 67866678 email: info@acotec.cn
























Lesion specific size matrix

Drug Eluting Balloon Catheter



Exquisite design ensures that the drug reaches the lesion

Drug Eluting Balloon Catheter





- From 2.0 mm to 4.0 mm balloon diameter, with half size in diameter
- From 20 mm to 300 mm balloon lengths
- Usable shaft length is 90/150cm
- Matching 0.014 guidewire



Particle size of the drug coating under 8 8mmx10.0k electron microscope

Proprietary Coating Technology, optimized drug delivery

- Paclitaxel microcrystalline (micron) coating
- Lipophilic magnesium stearate (nanoscale) carrier
- Paclitaxel microcrystals to carrier volume ratio 50:1
- >99% of the particles in downstream are smaller than 25 microns in diameter



Coating drug, then folding the ballon

drug is on the outer surface of the balloon.

drug coating is protected by the balloon folding

• 70% of the drug coating was protected by balloon folding, and the drug loss was <10% when it was been washed for one minute in the simulation of blood flow

≈30% of the




Breakthrough technology certification in China and U.S.

Drug Eluting Balloon Catheter

1 Year results of the AcoArt II BTK DCB trial 1

Results of 6 months of angiography and 12 months clinical follow-up



Primary endpoint

Secondary endpoint

	DCB	PTA	P
Death@12 months	1.7% (1/59)	3.6% (2/56)	0.532
Major Amputation@12 months	1.7% (1/59)	1.8% (1/56)	0.971

1 Year results of the AcoArt BTK Italy trial with DCB ²



	DCB	РТА	P
Death@12 months	7.7% (4/52)	13.2% (7/53)	0.2
Major Amputation@12 months	0	0	



















